Patient Steering Isn’t Isolated — It’s a Pattern of Insurer Overreach

In Part 1 of our series, we explained the concept of patient steering through Preferred Provider Networks (PPNs). In Part 2, we showed how this behaviour directly harms patients prescribed GLP-1 medications like Ozempic and Wegovy.

But here’s the bigger truth:

These aren’t isolated cases. They’re part of a systemic pattern of insurer overreach.

Across Canada, we’re seeing:

• Exclusive arrangements between insurers and corporate pharmacy chains.
• Confusing “voluntary” programs that still pressure patients to switch.
• Fragmentation of care, where insurance policy design determines your pharmacist — not your choice, not your doctor, and not your needs.

The Canadian Pharmacists Association (CPhA) and patient advocates have already sounded the alarm, warning that payer-directed care undermines patient trust and safety. Even regulators like the Ontario College of Pharmacists and the Ministry of Health have acknowledged concerns.

At Centrum Pharmacy, we believe this trend threatens the foundation of primary care. Patients need continuity, not corporate steering. That’s why our model — the 4 C’s: Complete, Comprehensive, Caring, Connected Care — is built to protect patients from these systemic risks by keeping pharmacy care integrated with family medicine.

👉 This is Part 3 of our series on insurer overreach. In Part 4, we’ll outline what patients, providers, and policymakers can do to push back.

Disclaimer: The medical information on this site is provided as an information resource only and is not to be used or relied on for any diagnostic or treatment purposes. This information does not substitute for professional diagnosis and treatment. Please do not initiate, modify, or discontinue any treatment, medication, or supplement solely based on this information. Always seek the advice of your healthcare provider first. Full Disclaimer.